Jefferies Financial Group’s Xenon Pharmaceuticals XENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-66,500
Closed -$2.62M 1897
2024
Q3
$2.62M Sell
66,500
-2,500
-4% -$101K 0.02% 502
2024
Q2
$2.69M Buy
69,000
+3,363
+5% +$134K 0.03% 463
2024
Q1
$2.83M Sell
65,637
-1,086
-2% -$50K 0.03% 474
2023
Q4
$3.07M Buy
66,723
+55,635
+502% +$1.97M 0.02% 546
2023
Q3
$379K Buy
11,088
+2,319
+26% +$86.7K ﹤0.01% 1162
2023
Q2
$338K Buy
+8,769
New +$349K ﹤0.01% 1289
2023
Q1
Sell
-19,500
Closed -$720K 2038
2022
Q4
$769K Buy
+19,500
New +$710K 0.01% 933

Other funds holding XENE

Jefferies Financial Group's XENE Position: Q4 2024 in Review

Jefferies Financial Group sold out of Xenon Pharmaceuticals (XENE) in Q4 2024, closing a stake of 66,500 shares — an estimated $2.62M sold.

Jefferies Financial Group first reported a position in XENE in Q4 2022 and held it in 7 quarters. The position peaked at $3.07M in Q4 2023. 209 funds tracked by Wall St. Rank hold XENE as of Q4 2024.

  • Jefferies Financial Group reported no remaining Xenon Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Jefferies Financial Group sold 66,500 Xenon Pharmaceuticals shares in Q4 2024, an estimated $2.62M.
  • Jefferies Financial Group first reported a position in Xenon Pharmaceuticals in Q4 2022 and held it in 7 quarters.
  • Jefferies Financial Group's Xenon Pharmaceuticals position peaked at $3.07M in Q4 2023.
  • 209 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2024.

Based on Jefferies Financial Group's 13F filing for Q4 2024, filed 14 Feb 2025.